High Frequency of Adenomyosis in Postmenopausal Breast Cancer Patients Treated with Tamoxifen

article OA: closed CC0 ⤵ 40 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-06

Adenomyosis was diagnosed in 53.6% of postmenopausal breast cancer patients treated with tamoxifen, significantly more than the 18.2% in patients not treated with tamoxifen.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Pathologic evaluation for adenomyosis in uterine specimens as well as demographic characteristics, health habits and risk factors for endometrial cancer were compared in 28 postmenopausal breast cancer patients with tamoxifen (TAM) treatment and in 11 similar patients without TAM treatment in order to determine the association between postmenopausal TAM exposure and the frequency of adenomyosis. The same comparison was also made between TAM-treated patients with adenomyosis and TAM-treated patients without adenomyosis. Adenomyosis was histologically diagnosed in 53.6% TAM-treated patients and in 18.2% non-TAM patients. Overall, there were no significant statistical differences in all parameters tested between the 2 groups, as well as between the TAM-treated patients with adenomyosis and the TAM-treated patients without adenomyosis. It can be concluded that adenomyosis was significantly more common among postmenopausal breast cancer patients who were treated with TAM as compared to similar patients without TAM treatment (p = 0.0186). This significant high rate of adenomyosis may be attributed to the continuous and unopposed exposure to TAM. It is, however, impossible to predict which postmenopausal breast cancer patient will develop adenomyosis after treatment with TAM.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Antineoplastic Agents, Hormonal Breast Neoplasms Endometriosis Postmenopause Postmenopause Tamoxifen Uterine Diseases Aged Antineoplastic Agents, Hormonal Antineoplastic Agents, Hormonal Breast Neoplasms Breast Neoplasms Endometriosis Endometriosis Endometriosis Estradiol Estradiol Female Follow-Up Studies Humans

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (40)

Source provenance

europepmc
last seen: 2026-06-11T06:19:48.454388+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:52.568893+00:00
License: CC0 · commercial use OK